Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Complication of Hemodialysis Clear all
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

NCT00372489
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis

NCT03327909
View directory record Official record
Conditions
ESRD, Hemodialysis Complication, Blood Pressure
Interventions
TAKE vs. HOLD
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Menlo Park, California • San Carlos, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients

NCT00477516
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
exposure to a high-calcium dialysate bath
Procedure
Lead sponsor
James B. Wetmore, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 4 Interventional

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

NCT00062699
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Zemplar (paricalcitol injection), Calcijex
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Effect of Exercise on Endothelial Function and Vascular Compliance in Chronic Kidney Disease

NCT01068314
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Repetitive arm exercise
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure

NCT00002047
View directory record Official record
Conditions
HIV Infections, Kidney Failure, Chronic
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 2:12 PM EDT
Not listed Not applicable Interventional

Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients

NCT03311321
View directory record Official record
Conditions
Cardiovascular Diseases, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5, Vitamin K Deficiency, Hemodialysis
Interventions
Vitamin K2 (menaquinone-7; 360-mcg/d), Placebo-Control
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

NCT04178577
View directory record Official record
Conditions
Renal Impairment
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Lipid Infusion in Dialysis Patients With Endotoxemia

NCT00506454
View directory record Official record
Conditions
Fatigue, End Stage Renal Disease (ESRD)
Interventions
Lipidose, Placebo
Drug
Lead sponsor
Sepsicure
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function

NCT03874117
View directory record Official record
Conditions
Hemodialysis, Kidney Failure, Chronic
Interventions
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis, Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Palo Alto, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Cook Enforcer Post-Market Study

NCT03552289
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, Conventional angioplasty balloon catheters
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Darien, Connecticut • Newark, Delaware + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

A Safety Study of Pentoxifylline for the Treatment of Anemia

NCT01102218
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Erythropoietin, Pentoxifylline
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

NCT00792857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP201 Injection, Doxercalciferol
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Jun 10, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)

NCT05465044
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
Interventions
Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule, Thrice-Weekly Hemodialysis
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Long Beach, California • West Los Angeles, California • West Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Not applicable Interventional

The Effect of Nighttime Dialysis on the Inflammation of Kidney Failure

NCT00234130
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
nocturnal vs conventional dialysis
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

A Communication Tool to Assist Older Adults Facing Dialysis Choices

NCT04466865
View directory record Official record
Conditions
Palliative Care, Kidney Failure, Chronic, Decision Making, Decision Support Techniques, Renal Dialysis, Dialysis, Kidney Diseases, Nephrologists, Decision Aid, End of Life, End-Stage Renal Disease, Late-Stage Renal Disease, Communication, Life-Supporting Treatments
Interventions
Best Case/Worst Case communication tool training
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 2:12 PM EDT
Withdrawn Phase 4 Interventional

Spironolactone Safety in Dialysis Patients

NCT00328809
View directory record Official record
Conditions
End Stage Renal Disease, Congestive Heart Failure
Interventions
spironolactone
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jun 10, 2026, 2:12 PM EDT
Completed No phase listed Observational

Effect of Parenteral Iron Therapy on Inflammatory Response and Oxidative Stress Chronic Hemodialysis

NCT00583973
View directory record Official record
Conditions
Hemodialysis, Chronic Kidney Disease, Inflammation
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

NCT04527328
View directory record Official record
Conditions
Cognitive Impairment, End Stage Renal Disease
Interventions
AKST1210, Sham Control (No Intervention), Hemodialysis
Device · Other · Procedure
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia

NCT00614679
View directory record Official record
Conditions
End-Stage Renal Disease, Hemodialysis Catheter-associated Infection
Interventions
catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Jun 10, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

NCT00293202
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Kaysen, George A., M.D., Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

NCT03873038
View directory record Official record
Conditions
Renal Dialysis, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jun 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

NCT00440648
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
sevelamer carbonate, sevelamer hydrochloride, sevelamer hydrochloride, sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Mobile, Alabama • Riverside, California • Greenwood Village, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Jun 10, 2026, 2:12 PM EDT